CAS 1201902-80-8: MLN9708

MLN9708

4-(Carboxymethyl)-2-((R)-1-(2-(2,5-Dichlorobenzamido)Acetamido)-3-Methylbutyl)-6-Oxo-1,3,2-Dioxaborinane-4-Carboxylic Acid

Applications MLN-9708 is a novel proteasome inhibitor. References Kupperman, Erik., et al.: Cancer Res., 70, 1970 (2010);

MLN2238 inhibits 20S proteasome's β5 site (Ki50=0.93 nM, IC50=3.4 nM), active form of Ixazomib Citrate in solutions/plasma.

Ixazomib Citrate (MLN9708) is a proteasome inhibitor that belongs to the class of investigational agents. It has minimal toxicity and is being investigated for use in the treatment of multiple myeloma, a type of cancer that starts in the bone marrow. Ixazomib Citrate inhibits the activity of proteasomes, which are cellular structures responsible for degrading proteins. This inhibition leads to an increase in the number of cells with damaged DNA and an increase in apoptosis. Ixazomib Citrate synergizes with other chemotherapeutic agents, such as bortezomib, to promote apoptosis by activating caspases and decreasing cell proliferation. The biochemical properties of this drug include its ability to inhibit protein synthesis by inhibiting eukaryotic ribosomes and its ability to bind to DNA at specific sites.